Form 8-K - Current report:
SEC Accession No. 0000950170-25-068020
Filing Date
2025-05-09
Accepted
2025-05-09 16:10:09
Documents
13
Period of Report
2025-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atha-20250509.htm   iXBRL 8-K 51827
2 EX-99.1 atha-ex99_1.htm EX-99.1 135349
3 GRAPHIC img247042425_0.jpg GRAPHIC 59423
  Complete submission text file 0000950170-25-068020.txt   399231

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20250509.xsd EX-101.SCH 26991
15 EXTRACTED XBRL INSTANCE DOCUMENT atha-20250509_htm.xml XML 4888
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

EIN.: 453368487 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39503 | Film No.: 25930501
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)